August 6, 2018 Comments Off on Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study Posted in: Guest content, Insights This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…
August 1, 2018 Comments Off on Ten years of biosimilars in Europe: development and evolution of the regulatory pathways Posted in: Insights This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract…
The post Ten years of biosi…